Recurrence scores from gene expression profiling tests are used increasingly to determine the likely benefit of adjuvant chemotherapy in early stage breast cancer. Discussions with anxious patients about risk and uncertainty and the rationale for different treatment recommendations can be complex and confusing. The TARGET research programme aimed to assist clinicians with these conversations.

In order to help both patients and clinicians we developed an educational program comprising a set of filmed scenarios of doctors talking to patients with different characteristics and risk test results. The films below are now provided free to facilitators and educational organisations.The scenarios demonstrate the communication challenges with the different types of patients.

High risk - based on EndoPredict score

^ Top

Intermediate risk based on OncotypeDX score

^ Top

High risk based on OncotypeDX score

^ Top

Low risk based on OncotypeDX score

^ Top

Low risk based on EndoPredict score

^ Top